Peptide powder Semaglutide CAS：910463-68-2

semaglutide, a new generation of GLP-1 (glucagon-like peptide-1) analogues currently under development, has a particularly outstanding effect in treating type 2 diabetes. Compared with liraglutide, somallutide has a longer fatty chain and increased hydrophobicity. However, somallutide has been modified with short-chain PEG, significantly enhancing its overall hydrophilicity.